Get the Stockscreener App
2.94
0.68%
-0.02
Xbiotech Inc stock is traded at $2.94, with a volume of 44,592.
It is down -0.68% in the last 24 hours and down -16.48% over the past month.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
See More
Previous Close:
$2.96
Open:
$2.96
24h Volume:
44,592
Relative Volume:
0.89
Market Cap:
$95.12M
Revenue:
$4.01M
Net Income/Loss:
$-38.53M
P/E Ratio:
-2.3333
EPS:
-1.26
Net Cash Flow:
$-32.27M
1W Performance:
+2.08%
1M Performance:
-16.48%
6M Performance:
-61.01%
1Y Performance:
-63.75%
1-Day Range:
$2.92
$3.0944
1-Week Range:
$2.92
$3.381
52-Week Range:
$2.65
$9.45
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.94 | 95.12M | 4.01M | -38.53M | -32.27M | -1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBiotech (NASDAQ:XBIT) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
XBiotech Inc. (NASDAQ:XBIT) Shares Sold by American Century Companies Inc. - Defense World
XBiotech stock plunges to 52-week low at $2.91 amid market challenges - Investing.com Canada
XBiotech Inc. (NASDAQ:XBIT) Short Interest Down 23.1% in March - MarketBeat
XBiotech Announces Board Member Retirement - TipRanks
XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat
Bank of New York Mellon Corp Has $360,000 Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of XBiotech Inc. -- XBIT - ACCESS Newswire
XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results - MarketBeat
Stocks Recover Some of This Week’s Losses as US Shutdown Seems Averted - TradingView
Stocks Rally as US Government Shutdown Risks Recede - TradingView
Tariff Worries Pressure Stocks - TradingView
XBiotech Inc.'s (NASDAQ:XBIT) 18% gain last week benefited both retail investors who own 49% as well as insiders - Simply Wall St
XBIT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money - ACCESS Newswire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against XBiotech, Inc. (XBIT) and Lead Plaintiff Deadline: February 1, 2016 - ACCESS Newswire
Investor Network: XBiotech, Inc. to Host Earnings Call - ACCESS Newswire
XBiotech Inc. (NASDAQ:XBIT) Sees Large Growth in Short Interest - MarketBeat
Head to Head Contrast: Aurinia Pharmaceuticals (NASDAQ:AUPH) and XBiotech (NASDAQ:XBIT) - Armenian Reporter
XBiotech stock plunges to 52-week low, touches $3.03 - Investing.com India
XBiotech stock plunges to 52-week low, touches $3.03 By Investing.com - Investing.com Canada
Head-To-Head Analysis: Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. XBiotech (NASDAQ:XBIT) - Defense World
Investing in XBiotech Inc (XBIT) might be a great opportunity, but the stock is a bit overvalued - US Post News
XBiotech Inc. (NASDAQ:XBIT) Short Interest Update - Defense World
XBIT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into XBiotech Inc. and Encourages Investors to Contact the Firm - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc.XBIT - PR Newswire
XBiotech stock hits 52-week low at $3.5 amid market challenges - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out - Markets Insider
XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Barclays PLC Boosts Stock Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation - Markets Insider
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm - Kilgore News Herald
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out - Markets Insider
Jane Street Group LLC Acquires Shares of 11,141 XBiotech Inc. (NASDAQ:XBIT) - Defense World
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws - GlobeNewswire Inc.
XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35% - Yahoo Finance
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):